1334037-10-3

Basic information

• Product Name: (Z)-2-(1-ethoxyethoxy)-N'-hydroxy-3-methoxy-3-(4-morpholinophenyl)propanimidamide
• Synonyms: (Z)-2-(1-ethoxyethoxy)-N'-hydroxy-3-methoxy-3-(4-morpholinophenyl)propanimidamide
• CAS NO: 1334037-10-3
• Molecular Weight: 367.445
• Mol File: 1334037-10-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (Z)-2-(1-ethoxyethoxy)-N'-hydroxy-3-methoxy-3-(4-morpholinophenyl)propanimidamide(CAS DataBase Reference)
• NIST Chemistry Reference: (Z)-2-(1-ethoxyethoxy)-N'-hydroxy-3-methoxy-3-(4-morpholinophenyl)propanimidamide(1334037-10-3)
• EPA Substance Registry System: (Z)-2-(1-ethoxyethoxy)-N'-hydroxy-3-methoxy-3-(4-morpholinophenyl)propanimidamide(1334037-10-3)

Safety Data

• Hazardous Substances Data: 1334037-10-3(Hazardous Substances Data)

Upstream product

• 1333473-17-8 2-(1-ethoxyethoxy)-3-methoxy-3-(4-morpholinophenyl)propanenitrile 
• 1333473-16-7 2-hydroxy-3-methoxy-3-(4-morpholinophenyl)propanenitrile 
• 1333473-15-6 2-methoxy-2-(4-morpholinophenyl)acetaldehyde 
• 1333472-27-7 N,2-dimethoxy-N-methyl-2-(4-morpholinophenyl)acetamide 
• 1204-86-0 4-(4-morpholinyl)benzaldehyde 

Downstream Products

• 1333473-18-9 4-(4-(2-(5-(4-bromo-3,5-dimethoxyphenyl)-1,2,4-oxadiazol-3-yl)-2-(1-ethoxyethoxy)-1-methoxyethyl)phenyl)morpholine 
• 1333471-88-7 1-(5-(4-bromo-3,5-dimethoxyphenyl)-1,2,4-oxadiazol-3-yl)-2-methoxy-2-(4-morpholinophenyl)ethanone 
• 1333473-19-0 1-(5-(4-bromo-3,5-dimethoxyphenyl)-1,2,4-oxadiazol-3-yl)-2-methoxy-2-(4-morpholinophenyl)ethanol 

Relevant articles and documents

PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS

Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. Also disclosed are compositions containing a compound in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.